The study focuses on the current state of curative mud deposits in Estonia as of 2022, examining changes over the past decade and providing essential information on curative mud quality. Total of 64 curative mud samples were collected in 2022, marking the first investigation into hazardous substances such as phenols, petroleum products, and pesticides. The study encompassed analyses of organic and mineral matter content, grain size, microbiology, and heavy metal concentrations, totalling 1649 measurements. Comparisons with previous data revealed stable organic matter concentrations in lake and marine sediments over the last decade. Microbiological contamination in curative mud samples was relatively low, indicating cleanliness. Petroleum product concentrations varied, with Haapsalu at 42 mg/kg, Värska at 118.6 mg/kg, and Käina below the limit of quantification. Phenol concentrations were generally below the limit of quantification, except for Värska. Pesticides were found in Värska samples, but in other sediments, levels were below the limit of quantification. Average heavy metal concentrations in curative mud decreased between 2013-2014 and 2022, remaining below the target value. The study's results are crucial for curative mud-related entrepreneurship in Estonia, facilitating compliance with the new regulatory standards. The comprehensive data obtained will contribute to the consistency and efficacy of curative mud-related practices in the country.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455685 | PMC |
http://dx.doi.org/10.1007/s10653-024-02250-6 | DOI Listing |
Blood Adv
December 2024
Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, University Hospital Ulm, Ulm, Germany.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)-based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020.
View Article and Find Full Text PDFEnviron Geochem Health
October 2024
Institute of Ecology, School of Natural Sciences and Health, Tallinn University, Uus-Sadama 5, 10121, Tallinn, Estonia.
Transplant Cell Ther
November 2024
Division of Hematology and Oncology, Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, New York. Electronic address:
Despite the established potentially curative role of allogeneic hematopoietic cell transplantation (allo-HCT) in managing myelofibrosis (MF), the choice of alternative donors for patients lacking matched donors remains a challenge, and the optimal graft source in this disease entity continues to be an ongoing debate. We aimed to evaluate the impact of donor type: umbilical cord blood transplant supported with CD34+ selected haploidentical donor (haplo-cord) versus adult matched related donor (MRD) and matched unrelated donor (MUD) in 40 adult patients with primary or secondary MF, including those progressing to accelerated phase (AP) or blast phase (BP), who underwent their first allo-HCT. The primary objective of this study was to analyze the impact of stem cell source on primary endpoints of overall survival (OS), graft-versus-host disease, and non-relapse mortality (NRM).
View Article and Find Full Text PDFRinsho Ketsueki
August 2024
Department of Hematology, Japanese Red Cross Medical Center.
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment option for multiple myeloma (MM), but few patients are eligible due to its high risk of treatment-related toxicity and relapse. Here, we report the feasibility and efficacy of allo-SCT after myeloablative conditioning with 8 Gy of total body irradiation (TBI) for reducing relapse of MM. We retrospectively analyzed data from 30 consecutive patients who received allo-SCT for MM after 8 Gy of TBI at Japanese Red Cross Medical Center between 2012 and 2021.
View Article and Find Full Text PDFHemasphere
July 2024
Department of Pediatric Hematology CHU Hôtel Dieu Nantes France.
For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option. In the case of increased blasts (cMDS-IB), the benefit of pretransplant cytoreductive therapy remains controversial. In this multicenter retrospective study, the outcomes of all French children who underwent allo-HSCT for cMDS reported in the SFGM-TC registry between 2000 and 2020 were analyzed ( = 84).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!